Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/4/2017
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/4/2017
Wake Forest University Health Sciences
312
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated:  4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
31
mi
from 43215
Columbus, OH
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated: 4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
31
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients
Status: Enrolling
Updated:  4/4/2017
Thomas Jefferson University
416
mi
from 43215
Philadelphia, PA
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients
Status: Enrolling
Updated: 4/4/2017
Thomas Jefferson University
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MNK-010 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/4/2017
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MNK-010 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/4/2017
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer
Restorative Yoga for Symptom Management and Stress Reduction in Women With Ovarian Cancer
Status: Enrolling
Updated:  4/4/2017
Wake Forest University Comprehensive Cancer Center
306
mi
from 43215
Winston-Salem, NC
Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer
Restorative Yoga for Symptom Management and Stress Reduction in Women With Ovarian Cancer
Status: Enrolling
Updated: 4/4/2017
Wake Forest University Comprehensive Cancer Center
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors
Status: Enrolling
Updated:  4/4/2017
OHSU Knight Cancer Institute
2027
mi
from 43215
Portland, OR
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors
Status: Enrolling
Updated: 4/4/2017
OHSU Knight Cancer Institute
2027
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Yoga Intervention for Cancer Survivors
Yoga Intervention for Cancer Survivors
Status: Enrolling
Updated:  4/5/2017
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Yoga Intervention for Cancer Survivors
Yoga Intervention for Cancer Survivors
Status: Enrolling
Updated: 4/5/2017
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Status: Enrolling
Updated:  4/5/2017
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Status: Enrolling
Updated: 4/5/2017
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Status: Enrolling
Updated:  4/5/2017
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Status: Enrolling
Updated: 4/5/2017
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
UCSF Comprehensive Cancer Center
2108
mi
from 43215
San Francisco, CA
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
UCSF Comprehensive Cancer Center
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
274
mi
from 43215
Chicago, IL
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
Holden Comprehensive Cancer Center at University of Iowa
460
mi
from 43215
Iowa City, IA
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
Holden Comprehensive Cancer Center at University of Iowa
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
Children's Hospital of New Orleans
799
mi
from 43215
New Orleans, LA
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
Children's Hospital of New Orleans
799
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
Maryland Medical Research Institute
342
mi
from 43215
Baltimore, MD
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
Maryland Medical Research Institute
342
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
345
mi
from 43215
Baltimore, MD
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
University of Minnesota Cancer Center
624
mi
from 43215
Minneapolis, MN
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
University of Minnesota Cancer Center
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
UMDNJ University Hospital
468
mi
from 43215
Newark, NJ
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
UMDNJ University Hospital
468
mi
from 43215
Newark, NJ
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
Kaiser Permanente Center for Health Research
2026
mi
from 43215
Portland, OR
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
Kaiser Permanente Center for Health Research
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated:  4/5/2017
Fox Chase Cancer Center - Philadelphia
420
mi
from 43215
Philadelphia, PA
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
Adolescent Diet, Hormones and Breast Cancer Susceptibility
Status: Enrolling
Updated: 4/5/2017
Fox Chase Cancer Center - Philadelphia
420
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients
Status: Enrolling
Updated:  4/6/2017
Vanderbilt-Ingram Cancer Center at Franklin
351
mi
from 43215
Nashville, TN
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients
Status: Enrolling
Updated: 4/6/2017
Vanderbilt-Ingram Cancer Center at Franklin
351
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients
Status: Enrolling
Updated:  4/6/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Nashville, TN
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients
Status: Enrolling
Updated: 4/6/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients
Status: Enrolling
Updated:  4/6/2017
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients
Status: Enrolling
Updated: 4/6/2017
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Impact of Secondary Lymphedema on Symptoms, Functional Status, and Quality of Life After Treatment in Patients With Head and Neck Cancer
The Impact of Secondary Lymphedema After Head and Neck Cancer Treatment on Symptoms, Functional Status, and Quality of Life
Status: Enrolling
Updated:  4/6/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Nashville, TN
Impact of Secondary Lymphedema on Symptoms, Functional Status, and Quality of Life After Treatment in Patients With Head and Neck Cancer
The Impact of Secondary Lymphedema After Head and Neck Cancer Treatment on Symptoms, Functional Status, and Quality of Life
Status: Enrolling
Updated: 4/6/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Impact of Secondary Lymphedema on Symptoms, Functional Status, and Quality of Life After Treatment in Patients With Head and Neck Cancer
The Impact of Secondary Lymphedema After Head and Neck Cancer Treatment on Symptoms, Functional Status, and Quality of Life
Status: Enrolling
Updated:  4/6/2017
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Impact of Secondary Lymphedema on Symptoms, Functional Status, and Quality of Life After Treatment in Patients With Head and Neck Cancer
The Impact of Secondary Lymphedema After Head and Neck Cancer Treatment on Symptoms, Functional Status, and Quality of Life
Status: Enrolling
Updated: 4/6/2017
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated:  4/6/2017
Sarah Cannon Research Institute
1161
mi
from 43215
Denver, CO
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated: 4/6/2017
Sarah Cannon Research Institute
1161
mi
from 43215
Denver, CO
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated:  4/6/2017
Yale Cancer Center
537
mi
from 43215
New Haven, CT
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated: 4/6/2017
Yale Cancer Center
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated:  4/6/2017
Barbara Ann Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated: 4/6/2017
Barbara Ann Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated:  4/6/2017
University of Pennsylvania Perelman School of Medicine
416
mi
from 43215
Philadelphia, PA
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated: 4/6/2017
University of Pennsylvania Perelman School of Medicine
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated:  4/6/2017
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Status: Enrolling
Updated: 4/6/2017
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in
Status: Enrolling
Updated:  4/6/2017
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in
Status: Enrolling
Updated: 4/6/2017
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
A Phase I Trial Of The Humanized Anti-GD2 Antibody (HU14.18K322A) In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Status: Enrolling
Updated:  4/10/2017
St. Jude Children's Research Hospital
507
mi
from 43215
Memphis, TN
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
A Phase I Trial Of The Humanized Anti-GD2 Antibody (HU14.18K322A) In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Status: Enrolling
Updated: 4/10/2017
St. Jude Children's Research Hospital
507
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Pilot Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Status: Enrolling
Updated:  4/11/2017
Riley Hospital for Children
166
mi
from 43215
Indianapolis, IN
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Pilot Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Status: Enrolling
Updated: 4/11/2017
Riley Hospital for Children
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated:  4/11/2017
Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated: 4/11/2017
Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated:  4/11/2017
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated: 4/11/2017
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated:  4/11/2017
Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo
mi
from 43215
Villejuif,
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Status: Enrolling
Updated: 4/11/2017
Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo
mi
from 43215
Villejuif,
Click here to add this to my saved trials
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study
Status: Enrolling
Updated:  4/11/2017
Northwestern University
274
mi
from 43215
Chicago, IL
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study
Status: Enrolling
Updated: 4/11/2017
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated:  4/11/2017
Fairfax Family Practice Centers
309
mi
from 43215
Fairfax, VA
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated: 4/11/2017
Fairfax Family Practice Centers
309
mi
from 43215
Fairfax, VA
Click here to add this to my saved trials
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated:  4/11/2017
Virginia Ambulatory Care Outcomes Research Network
344
mi
from 43215
Richmond, VA
Understanding the Value of Community Vital Signs in Primary Care
Understanding the Value of Community Vital Signs in Primary Care
Status: Enrolling
Updated: 4/11/2017
Virginia Ambulatory Care Outcomes Research Network
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
TKI258 in Castrate Resistant Prostate Cancer
An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma
Status: Enrolling
Updated:  4/12/2017
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
TKI258 in Castrate Resistant Prostate Cancer
An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma
Status: Enrolling
Updated: 4/12/2017
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery
Analysis of Technique Comparison With a Vacuum Erection Device as Part of an Erectile Rehabilitation Program Following Robotic Radical Prostatectomy: A Randomized Comparison of Methodology
Status: Enrolling
Updated:  4/12/2017
Ohio State University Medical Center
0
mi
from 43215
Columbus, OH
Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery
Analysis of Technique Comparison With a Vacuum Erection Device as Part of an Erectile Rehabilitation Program Following Robotic Radical Prostatectomy: A Randomized Comparison of Methodology
Status: Enrolling
Updated: 4/12/2017
Ohio State University Medical Center
0
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Colorado Cancer Center, Anschutz Medical Campus
1154
mi
from 43215
Denver, CO
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Colorado Cancer Center, Anschutz Medical Campus
1154
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Winship Cancer Institute at Emory University
432
mi
from 43215
Atlanta, GA
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Winship Cancer Institute at Emory University
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
345
mi
from 43215
Baltimore, MD
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Pittsburgh Medical Center Cancer Center
mi
from 43215
Pittsburgh, PA
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Pittsburgh Medical Center Cancer Center
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Washington University School of Medicine
397
mi
from 43215
St. Louis, MO
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Washington University School of Medicine
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Knight Cancer Institute at Oregon Health and Science University
2027
mi
from 43215
Portland, OR
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Knight Cancer Institute at Oregon Health and Science University
2027
mi
from 43215
Portland, OR
Click here to add this to my saved trials
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy
Status: Enrolling
Updated:  4/13/2017
Northwestern University
274
mi
from 43215
Chicago, IL
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy
Status: Enrolling
Updated: 4/13/2017
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials